The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy (“DGT”) clinical trial

IRVINE, Calif., June 29, 2020 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The University of Texas Health Science Center at Houston is the fifth large medical center to be part of the InFoods® clinical trial which includes:  Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers. UTH can now begin enrollment of patients in this trial.